We are live on ! Find out more
LEXX icon

Lexaria Bioscience

20 hedge funds and large institutions have $1.49M invested in Lexaria Bioscience in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

33% more funds holding

Funds holding: 15 → 20 (+5)

10.26% less ownership

Funds ownership: 21.9% → 11.63% (-10%)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

50% less capital inflows, than outflows

Capital inflows: $476K | Capital outflows: $958K

Holders
20
Holders Change
+5
Holders Change %
+33.33%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

LEXX Hedge Fund Activity: Q4 2023 in Review

20 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q4 2023, worth a combined $1.49M — down 16% from $1.77M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new LEXX positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 4 trimmed.

The largest buyer was Cowen and Company, opening a new position worth an estimated $330K. The largest seller was Armistice Capital, exiting entirely with an estimated $889K sold.

  • 20 institutional investors held Lexaria Bioscience (LEXX) as of Q4 2023, up from 15 in Q3 2023.
  • Funds reported $1.49M of Lexaria Bioscience stock for Q4 2023, down 16% quarter-over-quarter.
  • 6 funds opened new Lexaria Bioscience positions in Q4 2023 and 3 closed out, a net change of +3 holders.
  • The largest Lexaria Bioscience buyer in Q4 2023 was Cowen and Company, an estimated $330K added.
  • The largest Lexaria Bioscience seller in Q4 2023 was Armistice Capital, an estimated $889K sold.

Based on aggregated 13F filings for Q4 2023.